Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 155,578

Document Document Title
WO/2019/173367A1
Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells, and methods of treating sensory transduction disorders associated with a genetic defect.  
WO/2019/173636A1
Disclosed are Centryin chimeric antigen receptors (CARTyrins), CARTyrin transposons encoding CARTyrins of the disclosure, cells modified to express CARTyrins of the disclosure, as well as methods of making and methods of using the same f...  
WO/2019/169625A1
Disclosed is a mutant Cry2Aa insecticidal protein. Based on the amino acid sequence shown in SEQ ID NO. 1, the amino acid sequence of the insecticidal protein has one, two, or three mutations as follows: A) W78F; B) L144A, and C) R213E. ...  
WO/2019/173783A1
In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antige...  
WO/2019/173310A1
The present invention relates to a method of treating, mitigating, minimizing, or preventing HIV-1/AIDS by administering a CD24 protein to a subject in need thereof. Also provided herein is use of a CD24 protein in the manufacture of a m...  
WO/2019/173148A1
The present disclosure is concerned with cholesterol lowering agents including, but not limited to, statins and cyclodextrins, for the treatment of hepatic encephalopathy. This abstract is intended as a scanning tool for purposes of sear...  
WO/2019/173459A1
The present disclosure features compositions and methods of treating a cancer in a subject by administering to the subject a Skp2 inhibitor and an inhibitor of glycolytic metabolism (e.g., PKM2 inhibitor).  
WO/2019/173223A1
Provided are polynucleotides and viral vectors, particularly, alphavirus vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint pro...  
WO/2019/171261A1
A neurotrophic peptide for use as a medicament in the therapeutic treatment of neurodegenerative and/or inflammatory diseases is described. A pharmaceutical composition comprising the neurotrophic peptide in a pharmaceutically acceptable...  
WO/2019/169799A1
Disclosed are a biotinylated insulin antigen having a structure as represented by formula 1 and a biotinylation process thereof. The biotinylated insulin antigen of the present invention improves the coating efficiency of an insulin anti...  
WO/2019/103512A9
The present invention relates to a novel peptide or a partial sequence thereof for enhancing the expression efficiency of a target protein, and a fusion protein including the same. A novel peptide according to the present invention may i...  
WO/2019/173798A1
The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are suffic...  
WO/2019/173787A1
The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable ...  
WO/2019/171064A1
The present invention provides a method of detecting MAGEA4 in a sample. The method may comprise adding an anti-MAGEA4 antibody to the sample at a concentration in the range of from 2-20 μg/ml, incubating the antibody and the sample and...  
WO/2019/170837A1
There are disclosed fusion proteins comprising the bacterial protein FhuD2 and one or more copies of a heterologous polypeptide, polynucleotides and expression vectors encoding the fusion proteins and bacterial outer membrane vesicles co...  
WO/2019/170686A1
The present invention relates to a polypeptide which comprises or consists of - a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 55 to 67 of the...  
WO/2019/172703A1
The present invention relates to a composition for inhibiting a prokaryotic expression and a use thereof and, more specifically, to a composition for inhibiting an expression of Gram-positive bacteria, which includes an sRNA comprising a...  
WO/2019/173569A1
Compositions and methods for the detection and identification of Tick-Borne Relapsing Fever Borrelia sp. antibodies.  
WO/2019/173832A2
Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.  
WO/2019/173707A1
In some aspects, the disclosure relates to compositions and methods that are useful for treating inflammatory disorders and conditions. In some embodiments, the disclosure provides recombinant adeno-associated virus (rAAV) vectors and pa...  
WO/2019/173463A1
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines...  
WO/2019/173465A1
Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytok...  
WO/2019/169697A1
Disclosed is a hepatoma cell-targeting antimicrobial peptide chimera M27-39-HTPP and the use thereof, wherein same is obtained by the fusion of positions 27 to 39 of Musca domestica cecropin with a hepatocyte-targeting and penetrating pe...  
WO/2019/170918A1
The invention relates to a method for synthesising a peptide comprising the sequence His-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gl y-Gln-Ala-Ala-Y-Glu-Phe-lle-Ala-Trp-Leu-Val-Z-Gly-Arg-Gly, comprising enzymatically couplin...  
WO/2019/170774A1
The current invention concerns a feed additive comprising a bacterial culture or a processed bacterial culture and a method for enhancing the zootechnical performance of animals. The bacterial culture comprises an isolated lactic acid ba...  
WO/2019/171081A1
SP1 and SP2 exist at the core of a system for chloroplast protein removal, designated Chloroplast-Associated Protein Degradation (CHLORAD). This system targets chloroplast substrates for degradation, either as a homeostatic, quality-cont...  
WO/2019/170684A1
The present invention relates to a polypeptide which comprises or consists of: - a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 123 to 137 of ...  
WO/2019/172030A1
Provided is a method for collecting and detecting a tumor cell contained in a sample in distinction from a contaminant cell. A tumor cell contained in a sample can be collected and detected in distinction from a contaminant cell by detec...  
WO/2019/170160A1
Disclosed is a polypeptide compound, a preparation method, and an application thereof. The polypeptide compound has a structural formula represented by (poly-Bm)-K-(Cyclic-An); wherein poly-Bm is a linear peptide chain, K is Lysine (Lys,...  
WO/2019/172614A1
The present invention relates to a novel anticancer fusion protein and use thereof, and more specifically, provides a fusion protein in which a tumor necrosis factor (TNF) superfamily protein is joined to a self-assembled protein.  
WO/2019/173565A1
The invention relates generally to methods for preparing recombinant nucleosomes. In particular, the invention relates to methods for ligating a histone peptide onto a fully assembled recombinant nucleosome. The invention further relates...  
WO/2019/173334A1
The invention represents a solution for major unmet medical need in the field of ophthalmology. Accordingly, the invention provides compositions, e.g., an engineered Vascular endothelial growth factor (VEGF) chimeric polypeptide, compris...  
WO/2019/173441A1
Disclosed are methods of preparing replication incompetent viruses comprising a vector encoding a T cell receptor (TCR), or an antigen-binding portion thereof, having antigenic specificity for a mutated amino acid sequence encoded by a c...  
WO/2019/170895A1
The invention relates to a method for preparing a coupling product comprising the sequence Pq-Wv-His-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Y-Glu-Phe-lle-Ala-Trp-Leu-Val-Z-Gly-Arg- Gly, comprising enzymati...  
WO/2019/171252A1
A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.  
WO/2019/173324A1
The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provid...  
WO/2019/169504A1
We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP ...  
WO/2019/173401A1
Systems and methods for spatial graph convolutions in accordance with embodiments of the invention are illustrated. One embodiment includes a method for predicting characteristics for molecules, wherein the method includes performing a f...  
WO/2019/172358A1
Disclosed are: a novel treatment means which is effective against cancer and is suitable for practical use; and a novel substance which is useful as the treatment means. Provided are: a novel peptide derived from a partial region of HMGN...  
WO/2019/173687A1
Technologies for identifying one or more neoepitope peptides include generating a database that includes peptide sequences within a predefinited range of length of residues, assigning a prior probability to each of the peptide sequences ...  
WO/2019/173767A1
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of ...  
WO/2019/172605A1
Disclosed are a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing same as an active ingredient. The method...  
WO/2019/170702A1
The present invention relates to the field of immunogenic compositions and vaccines and the use of such compositions in medicine. More particularly, it relates to immunogenic fragments of UspA2 comprising an epitope and immunogenic compo...  
WO/2019/173289A1
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic ex...  
WO/2019/169227A1
The disclosure presents a platform for discovering novel insecticidal proteins from highly heterogeneous environmental sources. The methodology utilizes metagenomic enrichment procedures and unique genetic amplification techniques, which...  
WO/2019/165563A1
The present disclosure relates to genetically encoded low affinity, fluorescent Ca2+ indicators, which may be targeted to endoplasmic reticulum, the sarcoplasmic reticulum and/or the mitochondria. It also relates to polynucleotides, vect...  
WO/2019/166355A1
The present invention relates to a compound consisting of one or more peptides comprising the structure in the following order: A - L1 - B - L2 - C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha he...  
WO/2019/139645A9
Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the ...  
WO/2019/166617A1
The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.  
WO/2019/165957A1
Provided in the present invention is recombination sequence information of a key host factor, ANP32A/B, which is required for the replication of the influenza virus in a host. More specifically, the present invention relates to motifs 12...  

Matches 1 - 50 out of 155,578